Dr Joss Adams

Consultant Oncologist


I trained at St John's College, Cambridge from 1990 to 1995. I completed my junior medical training in Oxford. I undertook specialist training in clinical oncology in Oxford from 2001 to 2006. I have been a Consultant in Reading since 2006.

I am the principal investigator for clinical trials in lung and breast cancer at the Royal Berkshire Hospital, Reading.

I was the Clinical Governance Lead at the Berkshire Cancer Centre, within the Royal Berkshire Hospital, Reading between 2006 and 2011. I was the Clinical Lead for Chemotherapy at the centre between 2011 and 2017.

I am the Clinical Supervisor for specialist oncology trainees.

I have written chapters for the Oxford Handbook of Emergencies in Oncology and Problem Solving in Oncology.


Treatment information

Some of the principal treatments carried out by Dr Joss Adams at Spire include:


Other treatments

  • Hormone treatment
  • Immunotherapy
  • Radiotherapy

Get in touch

Important information about COVID-19 tests

COVID-19 testing or antibody tests are not available as a standalone service at Spire Dunedin Hospital.


Marketing Information

Spire would like to provide you with marketing information about products and services offered by Spire and by selected third-party partners. If you do not consent for us to process your personal data for marketing activities, we will still be able to contact you about your enquiry.

We may contact you by email, SMS or phone about your enquiry. If we try to contact you by phone (mobile and/or landline) and you are not available, we may leave you a voicemail message. We may also use your details to contact you about patient surveys we use for improving our service or monitoring outcomes, which are not a form of marketing.

Submit my enquiry

Additional information

Special clinical interests: Breast, lung and lymphoma (radiotherapy)

MA, MB BChir / St John's College, Cambridge / 1995
Master of Arts, Bachelor of Medicine

A Phase II, randomised, open-label study of Gemcitabine/Carboplatin first-line chemotherapy in combination with or without the antisense oligonucleotide Apatorsen (OGX-427) in advanced squamous cell lung cancers ESMO 2017

Addition of Apatorsen, an inhibitor of Hsp27, to first-line gemcitabine/carboplatin in advanced squamous cell lung cancer: Design of the Cedar Study. ASCO 2016

2017: Nominated for national Oncology Registrars' Forum Trainer Award.

2014: Cycled from Reading to Barcelona on a tandem with Nurse Consultant Mark Foulkes on a charity cycle ride to raise funds to facilitate the local delivery of chemotherapy for patients in West Berkshire.

I have accepted educational grants to fund attendance at both national and international cancer conferences. I have provided training and updates for pharmaceutical companies when requested. I have no financial interests in any pharmaceutical company.
Telephone 0118 955 3539
Private secretary Marilyn Barras
Private secretary telephone 0118 955 3539
Private secretary fax 0118 955 3519
Private secretary email marilyn.barras@nhs.net